Pharma services business Open Orphan said admission and dealings in its ordinary shares of 0.1 pence each on AIM and Euronext Growth Dublin would commence at 8am on Friday under the ticker ORPH

Pharma services business Open Orphan, formerly known as Venn Life Sciences, has resumed trading on the stock exchanges in Dublin and London following (...)

Venn Life Sciences unveiled full-year results for 2018 on Tuesday, which showed the company’s sales dropped to €14.3 million from €17.8 million for the previous year.

Dublin-listed drug clinical trials manager Venn Life Sciences, which is in the process of merging with dealmaker Cathal Friel’s pharma services busine(...)

Cathal Friel, who has taken over as chief executive at Venn Life Sciences following an agreement to merge it with his company, Open Orphan. Photograph: Fennell Photography

Leading corporate figure Cathal Friel is behind the proposed reverse takeover of listed clinical trials group Venn Life Sciences by pharma services bu(...)

Theratechnologies aims to improve the quality of life for HIV patients. Photograph: iStock

A Canadian speciality pharmaceutical company has appointed Dublin man Conor Walshe as general manager of its European subsidiary. Theratechnologies,(...)

Venn Life Sciences chief executive Tony Richardson. Venn has established full-service clinical research programmes and activities in 27 different countries

Clinical trials group Venn Life Sciences has signed a strategic collaboration with Open Orphan DAC as it seeks to increase its focus on rare diseases (...)

IPHA president GSK’s Aidan Lynch (centre); IPHA vice-president Paul Reid (Pfizer); and Bayer’s Itziar Canamasas with the Manifesto for Better Health ahead of the IPHA annual conference on November 8th. Photograph: Justin Mac Innes

Big Pharma in Ireland has an image problem. At least that’s how it sees it. “I think we are not seen as a trusted partner,” says Aidan Lynch, presid(...)

Venn Life Sciences chairman Allan Wood says that investment in business development should deliver an improved order book in future.

Shares in clinical trials group Venn Life Sciences fell to a new low after it reported a fall in sales and wider losses for the first six months of th(...)

Tony Richardson, Venn Life Sciences

Having assumed the role of chief executive of Venn Life Sciences in 2010, Tony Richardson quickly set about expanding the company, completing two acqu(...)

Venn Life Science provides clinical trials services to pharmaceutical and biotech companies.

Drug development firm Venn Life Sciences has raised £650,000 before expenses in a share sale. The company, which provides clinical trials services to(...)

Drug development firm Venn Life Sciences said it reported an overall loss of €1.5 million for last year as charges related to its investment in Dalkey(...)

  • 1
  • 2
  • 3
  • Next
  • Last »